EGFR and non-small cell lung carcinoma: Some data of mechanisms of resistance to first line osimertinib are already available as is now the standard of care for EGFR mutant [both T790M+ and T790M negative (T790M-)] NSCLC, including genomic alterations that are detectable by liquid biopsy as described below.